Acetaminophen

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Acetaminophen
   1. Pharmacist Assessment Report
   2. Acetaminophen: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Acetaminophen: Known uses and market status in Australia

Summary

The TxGNN deep-learning model produced candidates for Acetaminophen, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The model results are for research reference only and are not medical advice.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
10582Y	PHARMACY CARE PARACETAMOL	Tablet 500 mg	Valid

Safety Considerations

• Disease-related contraindications (knowledge graph, not label text): liver failure, liver disease, cirrhosis of liver, hepatic encephalopathy, hepatic coma and gallbladder disease.
• Drug Interactions: 100 interactions were identified. Those listed are mostly Minor. Moderate-level interactions include activated charcoal, glycerol phenylbutyrate and naltrexone. Minor interactions include anticholinergic and antimuscarinic agents (atropine, hyoscyamine, scopolamine, glycopyrronium), H2 blockers (cimetidine, ranitidine), metoclopramide and liraglutide.

Please also refer to the TGA-approved Product Information (PI) for warnings and contraindications, as label text was not available for this report.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---